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Abstract 
The development of atherosclerosis is the major etiological factor causing cardiovascular disease and 
constitutes a lipid-induced, chronic inflammatory and autoimmune disease of the large arteries. A 
long standing view of the protective role of B cells in atherosclerosis has been challenged by recent 
studies using B cell depletion in animal models. Whereas complete B cell deficiency increases 
atherosclerosis, depletion of B2 but not B1 cells reduces atherosclerosis. This has led to a re-
evaluation of the multiple potential pathways by which B cells can regulate atherosclerosis, and the 
apparent opposing roles of B1 and B2 cells. B cells, in addition to having the unique ability to 
produce antibodies, are now recognized to play a number of important roles in the immune system, 
including cytokine production and direct regulation of T cell responses. This review summarises 
current knowledge on B cell subsets and functions, and how these could distinctly influence 
atherosclerosis development.  
  
Introduction 
Cardiovascular disease remains a leading cause of death in the developed world and is growing in 
prominence worldwide, with 80% of cardiovascular deaths now occurring in low-middle income 
countries (1). Atherosclerosis constitutes a lipid-induced, chronic inflammatory and autoimmune 
disease of the large arteries (2–5), and is the major underlying cause of heart disease and stroke. 
Control of cholesterol and blood pressure are effective preventive therapies, however further demand 
remains to better target vulnerable, event-inducing plaques, or alternatively reduce development of 
vulnerability. Reducing the associated chronic inflammation sustaining the immune response is an 
important target for scientific and future therapeutic investigation. Despite a long known association 
with atherosclerosis, B cells and antibodies have not always been a research focus. Current 
knowledge from the immunology field defines diverse functions for B cells beyond antibody 
secretion, with multiple subsets playing a role in both innate and adaptive immunity. This, in 
combination with results from mouse models suggesting different types of B cells can enhance as 
well as protect from atherosclerosis, has reignited interest in how these abundant and multifunctional 
cells impact all stages of atherosclerosis development. This review first describes B cell subsets and 
functions, then summarises current views on the potential roles of B cells in atherosclerosis and 
future targets for research that could enable therapeutic targeting. 
B cell subsets and functions 
B cell development and the different B cell subsets characterized are reviewed in detail elsewhere 
(6–8). Broadly, B1 and B2 cells constitute the major 2 groups of B cells and can be considered part 
of the innate and adaptive immune systems, respectively. B2 cells develop in the adult bone marrow 
from hematopoietic stem cells through a well-characterized series of precursor stages (7), whereas at 
least some B1 cells develop in the fetal liver and are self-sustaining in the adult independently of 
HSCs (9,10) (Figure 1A). B cells are primarily found in secondary lymphoid organs (spleen and 
lymph nodes), blood and submucosa of the intestine and lung, but also adipose tissue, aortic 
adventitia and sites of inflammation (11). The primary and unique characteristic of B cells is the 
expression of surface antibody, or B cell receptor, and thus their major function as the source of 
antibody-producing plasma cells. Each B cell clonal lineage develops a unique B cell receptor 
through somatic genome rearrangement of the multi-gene immunoglobulin locus. The binding 
specificity and affinity of the B cell receptor to self or foreign antigen defines the fate of each B cell. 
In the steady state, a system has evolved that provides a repertoire depleted of highly autoreactive 
clones yet robust and diverse enough to target the multitude of potential antigens encountered. Thus, 
multiple checkpoints regulate developing B cells to hone the B cell repertoire through mechanisms 
including receptor editing, anergy and apoptosis (12,13). In addition to antigen, important regulators 
of B cell development and activation include B cell activating factor (BAFF), and a proliferation-
inducing ligand (APRIL) (14). BAFF is essential for B2 cell maturation beyond the Transitional-1 
(T1) stage in the spleen through interaction with BAFF receptor (BAFFR) (15–17). BAFF can also 
regulate survival, activation and function of both B1 and B2 cells through BAFFR and the alternative 
receptor TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor). 
APRIL is a BAFF homologue but interacts only with TACI and a third receptor BCMA (B cell 
maturation antigen), but not BAFFR. TACI is upregulated in activated B cells and plays complex 
roles in B cell proliferation, survival and antibody class switching (18–20) whereas BCMA is 
upregulated on plasma cells and is essential for plasma cell survival in the bone marrow by 
transducing APRIL signals in the plasma cell niche (21,22). 
B1 cells play a major role in maintaining the barrier function of mucosal surfaces and possess B cell 
receptors with germline-encoded specificities for common pathogen-associated epitopes and rarely 
undergo B cell receptor editing or maturation, thus are as much part of the innate as the adaptive 
immune system. B1 cells are the source of natural antibodies, which are produced independently of 
any external antigens. One major family of these epitopes are oxidation-associated epitopes and 
include phosphorylcholine (PC) and malondialdehyde (MDA) (23). Such epitopes are common in 
endogenous debris such as apoptotic and necrotic cells and modified lipoprotein particles, e.g. 
oxidized low density lipoprotein (oxLDL). Thus, natural antibodies (and other antibodies targeting 
these antibodies) play an important role in homeostatic clearance of dead cells and other debris 
including oxLDL, and may contribute significantly to clearance pathways in atherosclerosis. 
Mature B2 cells recirculate via the blood through secondary lymphoid organs where they may 
encounter antigens captured and displayed by macrophages and dendritic cells, in general as part of 
immune complexes with (presumably) low affinity, natural or previously produced antibodies. 
Depending on other signals and the precise location, B2 cells are then activated and proliferate, 
leading variously to short-lived plasma cells, long-lived plasma cells that migrate to the bone marrow 
and memory B cells that enable life-long immunological memory and more rapid responses upon 
subsequent antigen encounters (24) (Figure 1A). Bone marrow plasma cells can persist for years and 
continue producing antibodies, but re-exposure to the same antigens stimulates memory B cell 
activation and formation of new plasma cells. Marginal zone B2 cells bridge the functions of B1 and 
follicular B2 cells, possessing somatically rearranged B cell receptors but having a memory-like 
phenotype that allows a more rapid B1-like response that can be activated by innate signals like Il-5 
or toll-like receptor ligands. In addition to developmental antibody receptor diversification, mature 
B2 cells selected and activated by the presence of cognate antigen undergo two further changes to 
their B cell receptor (antibody) - class switching of the Fc region and mutagenesis of the antigen 
binding Fab region to enhance affinity. Affinity maturation occurs in proliferating activated B cells 
in the germinal centers (GC) of secondary lymphoid organs where higher affinity clones prevail 
through competition for antigen immobilized on follicular dendritic cells (25). 
Antibodies play a primary effector function in neutralizing and clearing pathogens, pathogen-
associated molecules and infected cells through a range of mechanisms, including antibody-
dependent cellular cytoxicity, recruitment of the complement system  and promoting phagocytosis 
(26–28). Antibodies also influence innate immune function and phenotype, particularly macrophage 
inflammatory activation through the Fc region binding to Fc receptors on the cell surface (26). 
B cells, like most immune cells, produce a range of cytokines with potent and diverse effects. For B 
cells, these include most prominently Il-6, Il-10 and TNF (29). B cells also respond to many 
cytokines including Il-6, TNF, IFN-α, Il-4, Il-5, and IFN-γ. More recently, a distinct subset of spleen 
B cells has been shown to be capable of GM-CSF production and that these cells can significantly 
influence innate immune functions (30). Alternatively, B cell derived MCP-3 (Ccl7) is critical to 
monocyte mobilization in response to myocardial infarction with B cell depletion leading to reduced 
infarct area and improved heart function (31). 
B cells also regulate their adaptive immune counterparts, T cells, through antigen presentation and 
co-stimulation (32). In general, B cells are not phagocytic like myeloid antigen presenting cells, and 
only antigen endocytosed while bound to the B cell receptor (surface antibody) is processed and 
presented on B cell MHCII molecules to helper CD4+ T cells. Although dendritic cells act as 
primary activators of helper T cells, in many cases B cell – helper T cell interactions are critical in 
sustaining and regulating the nature of both T cell and B cell responses, for example in response to 
lower antigen levels (33). 
Not all B cells require the presence of cognate antigen or the presence of helper T cells for their 
activation and differentiation into plasma cells. B1 cells and certain B2 cell subsets, such as marginal 
zone B cells, can be activated directly by pathogen-associated molecular patterns, for example toll-
like receptor ligands, or cytokines such as IFN-α, Il-1β and Il-5 (34,35). In contrast, responses to 
protein antigens are commonly T cell dependent and require ongoing contact with antigen, 
costimulation and cytokines; the latter two signals received from specialized follicular helper T cells. 
BAFF and APRIL also play prominent roles in B cell activation in addition to being critical to 
homeostatic maintenance (16,17,36). Thus, both innate and adaptive immune pathways could lead to 
B cell activation in atherosclerosis (Figure 1B). 
Association of B cells and autoantibodies with atherosclerosis 
The humoral nature of B cell antibody responses suggests a remote regulation of atherosclerosis is 
most likely and most important. Furthermore, a number of other remote pathways negate a need for 
the presence of B cells within or adjacent to plaques for them to be important. These include T cell 
responses in spleen and lymph node, regulation of innate cell differentiation, monocyte mobilization 
from bone marrow, and their presence at alternative sites of cardiovascular disease-associated 
inflammation such as adipose tissue. Nevertheless, B cells can be found in plaques but are more 
often found at adventitial sites close to plaques (37–39). Initial reports suggested these cells may be 
plasma cells, whereas a recent report concluded that these B cells are most likely B2-derived 
plasmablasts, with evidence of local affinity maturation occurring in both adventitia and plaque, and 
the presence of a limited number of class-switched clones (40). The adventitia is a well-recognised 
site for immune responses (41), and advanced human and mouse atherosclerosis leads to the 
development of tertiary lymphoid organs in the adjacent adventitia (38,42). This suggests a potential 
for local B cell responses in advanced human atherosclerosis and thus ongoing regulation of plaque 
status. Whether adventitial immune responses and cell accumulation also occur in symptomatic 
coronary and carotid plaques is unclear, however it is easy to envisage aorta-originating B cell and T 
cell responses regulating plaques at other sites. Very recently, a study examining whole blood global 
gene co-expression identified a strong indication of B cell dysregulation in coronary heart disease 
patients compared to controls (43) and another showed activated CD86+ B cells associate with a 
higher risk of stroke (44). 
The presence of antibodies within atherosclerotic plaques is much more prominent than B cells 
themselves, with abundant IgM and IgG detected in human and mouse plaques (39,45,46).  
Circulating levels of modified LDL-reactive antibodies also associate with atherosclerosis (47,48), as 
do those to heat shock protein 65 (49). Levels of both natural IgM antibodies and adaptive IgG 
antibodies reacting with moieties found in modified LDL and on apoptotic cells, e.g. phophocholine 
or malondialdehyde, are associated with atherosclerotic burden in many studies, although not all 
(50–52). Interestingly, IgM levels decline with age (53), consistent with studies showing an inverse 
correlation with disease and extensive experimental evidence of its protective influence (46,54). 
Overall, the prevailing view is that anti-oxLDL IgG is positively correlated whereas IgM is 
negatively correlated; however doubt still remains, particularly in the case of IgG. Equally, 
prospective studies have shown mixed results (52). For example, anti-modified LDL antibodies 
predicted myocardial infarction in type II diabetes patients in the VADT study (55), but there was no 
prognostic value in the EPIC-Norfolk study (56). A further impact of B cells on atherosclerosis is the 
association of other autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus 
erthyramatous and Sjorgren’s syndrome (57,58) with an increased risk of cardiovascular disease. 
How the presence of these autoimmune diseases influences cardiovascular disease is complex, but 
cross-reactivity of autoantibodies is one contributory mechanism as well as systemic pro-
inflammatory cytokines that may be induced in part dependently on autoantibodies. In RA, the 
correlation between oxLDL IgG antibodies and atherosclerosis seems more consistent (59–61). 
Recently, in SLE patients, levels of autoantibodies to dsDNA and Cardiolipin were associated with 
higher levels of noncalcified plaques, potentially more prone to rupture (62) and a previously 
unappreciated pro-atherosclerotic role for IgE antibodies was demonstrated in ApoE-/- mice (63). The 
functional roles and overall influence of antibodies in atherosclerosis are further discussed below. 
 
B cells regulate atherosclerosis – Evidence from mouse models 
Given the diverse functions and wide ranging impact of B cells on immune responses, it is 
unsurprising that B cell regulation of atherosclerosis is complex to dissect. Past studies suggesting a 
solely protective role for B cells in atherosclerosis must now be reinterpreted based on the divergent 
roles of different B cell subsets and their antibodies. The increased atherosclerosis in B cell-deficient 
(µMT), atherosclerotic-prone ApoE-/- mice (64) and splenectomized mice (65) could be primarily 
due to the lack of B1 cells and natural IgM (46,54), which plays a prominent role in opsonisation and 
non-inflammatory removal of oxLDL as well as apoptotic cells. In contrast to genetic deficiency of 
all B cells, anti-CD20 antibody treatment, which preferentially depletes B2 cells, leaving B1 cells 
largely intact, reduces atherosclerosis (66,67). Corroborating these studies, the specific lack of 
mature B2 cells in ldlr-/- mice transplanted with B cell activating factor receptor (BAFFR)-deficient 
bone marrow reduces atherosclerosis (68). The same is true for BAFFR-/- mice on the ApoE-/- 
background (69) and B cell-specific BAFFR deficiency (68). Resupplementation of B cell-deficient 
mice with spleen B2 cells reverses the reduction of atherosclerosis (67). However, other groups have 
shown protective effects of transferred spleen B cells (65,70), suggesting as yet unclear complexities 
and multiple potential mechanisms for B2 cell regulation of atherosclerosis. Doran et al (70) showed 
that the ability to home to the aorta through CCL20-CCR6 signaling was key for atheroprotection. It 
is not clear if this property was important to recruit a certain subset or to the localization of B cells in 
general to the adventitia. Further fractionation of B2 (or spleen) subsets, or transfer of B cells from 
appropriate knockout mice, will be necessary to determine these remaining questions. 
 
Mechanisms for B cell regulation of atherosclerosis 
There are 3 major modalities by which B cells could influence atherosclerosis, 1) through antibodies, 
2) through regulation of T cell responses via cell-cell contact, and 3) through production of 
cytokines. These different modalities may act through a variety of pathways and each has both anti- 
and pro- atherogenic potential. 
1) Multiple roles of antibodies in atherosclerosis 
Past studies have provided many useful insights into the potential roles for autoantibodies in 
atherosclerosis. However, the lack of complete discrimination between natural or innate-derived and 
adaptive antibodies, the use of immunization strategies that also stimulate natural antibody and 
regulatory T cell-mediated immune responses (71), and a focus on oxLDL targeting antibodies (72), 
means that the overall influence of B cell antibodies is still unclear. The most recognized and studied 
autoantigen in atherosclerosis is modified LDL, with epitopes from various forms targeted both by 
natural antibodies and B2 cell-derived, class-switched IgG antibodies. Hsp60 and 65, as well as β2 
glycoprotein I, are further autoantigens (73). Passive Ig transfer (intravenous immunoglobulin; IVIg) 
suppresses atherosclerosis (74). IVIg, used in other autoimmune diseases and transplant patients, is 
hypothesised to work through differential sialylation of the Fc portion, leading to 
immunosuppressive pathways via IL-33, Il-4 and induction of macrophage FcRIIb (75) as well as 
through induction of regulatory T cells (76). Although a number of modified LDL or apoB peptide 
based active immunization strategies consistently reduce atherosclerosis (77,78), their effects are 
primarily due to increased regulatory T cell responses, enhanced natural antibody production and a 
shift to Th2 IgG responses, thus may not represent endogenous humoral responses (71,79). Indeed, 
both immunogenic adjuvant-containing (77,78)  and tolerogenic (e.g. mucosal or oral) formulations 
(79,80) lead to enhanced Treg levels and reduced atherosclerosis. In contrast, immunization with 
Hsp65 can enhance atherosclerosis (81–83), whereas tolerogenic strategies targeting Hsp65 reduce 
atherosclerosis (84–86). Immunization against β2-GPI can also enhance atherosclerosis (87). The 
consequences of endogenous antibody responses are far better understood for IgM antibodies than 
IgG and other isotypes, as exemplified by the E06 monoclonal phospholipid-reactive IgM (88). It is 
likely that enhanced clearance of oxLDL, preventing its accumulation in plaque and foam cell 
formation, is a major mechanism for the action of B1 cell derived IgM (89). Interestingly, very 
recent data suggests that excessive IgM accumulation in plaque bound to necrotic and lipid debris 
could in fact be pro-inflammatory (90), emphasising the need for further investigation. A major 
effector pathway for IgG antibodies linked to atherosclerosis are the Fcγ receptors, of which there are 
both pro-inflammatory activating receptors (I, IIa, III and IV) and an inhibitory receptor (IIb) 
(26,91). A pathogenic role for IgG antibodies/immune complexes in atherosclerosis is supported by 
findings that mice lacking activating, pro-inflammatory Fcγ (IgG) receptors have reduced 
atherosclerosis (92,93), whereas mice lacking the inhibitory FcγRIIb have enhanced atherosclerosis 
(94). Immune complexes are known to activate macrophages (95), a central mediator of plaque 
formation via Fc receptors, and oxLDL immune complexes can promote foam cell formation. 
Different IgG isotypes have varying affinities for Fc receptors and thus different activatory capacity, 
for example IgG2a/c (different strains express a or c isoforms) in mice is highly activatory (26). 
IgG2c is mainly induced in association with Th1 type responses such as those which dominate 
atherosclerosis, accordingly anti-oxLDL IgG2c is commonly found in atherosclerotic mice 
(46,66,68,92). In addition, the pathogenic or protective role of the targeted antigen (e.g. oxLDL vs 
heat-shock proteins) could strongly influence the effects of humoral responses against it, i.e. 
targeting the clearly pro-atherogenic oxLDL autoantigen may well be protective, whereas 
endogenous responses to distinct autoantigens may in contrast be pathogenic. Thus, the 
consequences of endogenous IgG responses in atherosclerosis remain ill-defined and methods to 
specifically target them must be developed to improve our understanding. 
2) B cell regulation of atherogenic T cells 
Results from B2 cell depletion models (66–68) support a role for B2 cell potentiation of pro-
atherogneic CD4+ T cell effector responses. Each of these studies was associated with significantly 
reduced numbers of T cells in plaques as well as systemic decreases in pro-atherosclerotic IFN-γ 
producing T cells, whereas complete B cell deficiency results in enhanced plaque T cell levels (65). 
These B cell-deficient (µMT) mice have defective Th2 (Il-4) differentiation capacity due to an effect 
on DCs (96), which may partly be due to lack of antibody-mediated uptake and lysosomal targeting 
(97). B cell depletion therapy is also effective in reducing other T cell dependent chronic diseases 
such as multiple sclerosis and rheumatoid arthritis (reviewed in (98)). Conventional CD11chi 
dendritic cells are now recognised as the primary and non-redundant antigen presenting cells 
activating, as well as maintaining, naïve T cells. However, macrophages and B cells can also play 
prominent roles in presenting antigen to effector T cells and influencing the nature (Th1, Th2, Th17, 
Treg), power and longevity of effector T cell responses (98). It has not yet been investigated whether 
MHCII-mediated antigen presentation by B cells is important for their stimulation of pro-atherogenic 
CD4+ T cell responses. Co-stimulatory molecules such as CD40 and OX40, or cytokines like TNF or 
IL-6 are also likely candidates for future investigation. A recent study investigating RP105, a TLR 
receptor regulator, also supports an important role for TLR-mediated regulation of B cells in 
atherosclerosis (99). 
3) B cell-derived cytokines and atherosclerosis 
Kyaw et al (67) showed that transferred B2 cells promoted atherosclerosis in T cell (and B cell) 
deficient RAG2-/-/ApoE-/- mice, although to a lesser extent than in T cell-sufficient mice. This 
suggests there are both T cell dependent and independent mechanisms involved. Beyond antibodies, 
B cells are now recognised to modulate immune responses, particularly those initiating in the spleen, 
through cytokines. For example, B cells are a major source of MCP-3 (Ccl7) in response to 
myocardial infarction and promote heart injury through monocyte mobilization into the infarct site 
(31). Although not yet investigated in atherosclerosis, GM-CSF+ B cells, also characterized as B1-
like plasmablasts resident in the spleen marginal zone, could potentially play an important role in 
atherosclerosis. In contrast to these potentially pro-atherogenic B cells, Il-10 producing B cells are 
likely protective. Although rare ‘regulatory’ B cell subsets characterized by high CD1d, CD19 and 
CD5 expression are important IL-10 producers (also called B10 cells) (32), other groups suggest that 
more common B cell subsets including marginal zone and B1 cells may potentially produce IL-10 
given the correct environmental stimuli, such as TLR ligands (35). Indeed, switching B cells between 
Il-10 and Il-6 production is associated with functional regulation of experimental autoimmune 
encephalomyelitis (EAE), a model of multiple sclerosis (29). B cells are also reported to express 
further cytokines such as TNF, which may be important in regulating T cell responses (100). Thus B 
cell cytokine-mediated regulation of atherosclerosis merits further attention in future studies. 
Conclusion 
The characterization of heterogeneity within B cells has led to a better appreciation that B cells can 
play multiple roles in atherosclerosis, with different subsets playing potentially opposing roles. 
Recent studies in mice have revealed the source of B cell protective immunity as primarily IgM, 
strongly supported by numerous clinical studies assessing human circulating anti-oxLDL IgM levels, 
whereas despite multiple lines of indirect evidence, the jury is still out on the functional roles of IgG 
and the nature of pro-atherogenic B cell immunity. Current research is focused on determining 
through which of the distinct functional pathways B cells regulate atherosclerosis development and 
whether these can be translated into therapeutic strategies. An important question will be how closely 
the roles of murine B cell subsets match their human counterparts, given various differences in cell 
and antibody isotype subsets. Therapeutically, the BAFF/APRIL system may be a fruitful area of 
research; establishing their role in endogenous atherosclerotic B cell (and potentially other immune 
cell) responses could be important in both understanding the underlying causes and mechanisms, and 
in therapeutic interventions, since a number of BAFF and APRIL targeting monoclonal antibodies 
have been developed and are already in clinical trials for cancer and autoimmune diseases. This is 
further supported by data showing upregulated BAFF and APRIL in human plaques (101) and the 
association of increased BAFF with myocardial infarction (31). 
  
References 
1.  Mendis S, Pekka P, Norrving B. Global Atlas on cardiovascular disease prevention and control. World 
Health Organization; 2011.  
2.  Legein B, Temmerman L, Biessen EAL, Lutgens E. Inflammation and immune system interactions in 
atherosclerosis. Cell Mol Life Sci CMLS. 2013 Oct;70(20):3847–69.  
3.  Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights 
and therapeutic approaches. J Clin Invest. 2013 Jan 2;123(1):27–36.  
4.  Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011 
Mar;12(3):204–12.  
5.  Grundtman C, Wick G. The autoimmune concept of atherosclerosis. Curr Opin Lipidol. 2011 
Oct;22(5):327–34.  
6.  Cancro MP. Peripheral B-cell maturation: the intersection of selection and homeostasis. Immunol Rev. 
2004 Feb;197:89–101.  
7.  Hardy RR, Kincade PW, Dorshkind K. The protean nature of cells in the B lymphocyte lineage. 
Immunity. 2007 Jun;26(6):703–14.  
8.  Montecino-Rodriguez E, Dorshkind K. New perspectives in B-1 B cell development and function. 
Trends Immunol. 2006 Sep;27(9):428–33.  
9.  Kantor AB, Herzenberg LA. Origin of murine B cell lineages. Annu Rev Immunol. 1993;11:501–38.  
10.  Duan B, Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev. 2006 Jul;5(6):403–8.  
11.  Campbell KA, Lipinski MJ, Doran AC, Skaflen MD, Fuster V, McNamara CA. Lymphocytes and the 
adventitial immune response in atherosclerosis. Circ Res. 2012 Mar 16;110(6):889–900.  
12.  Scholz JL, Cancro MP. Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunol 
Lett. 2012 Mar 30;143(1):2–8.  
13.  Von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat 
Immunol. 2010 Jan;11(1):14–20.  
14.  Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol. 2011 Aug;32(8):388–
94.  
15.  Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential 
role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 
2001 Sep 14;293(5537):2111–4.  
16.  Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis 
requires B cell activation factor production by radiation-resistant cells. J Exp Med. 2003 Sep 
15;198(6):937–45.  
17.  Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating 
factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 
Baltim Md 1950. 2004 Aug 15;173(4):2245–52.  
18.  Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, et al. Activation and accumulation of 
B cells in TACI-deficient mice. Nat Immunol. 2001 Jul;2(7):638–43.  
19.  Tsuji S, Cortesão C, Bram RJ, Platt JL, Cascalho M. TACI deficiency impairs sustained Blimp-1 
expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood. 2011 Nov 
24;118(22):5832–9.  
20.  Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, Dobles M, et al. TACI, unlike BAFF-R, is 
solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and 
plasmablasts. Blood. 2008 Feb 1;111(3):1004–12.  
21.  O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for 
the survival of long-lived bone marrow plasma cells. J Exp Med. 2004 Jan 5;199(1):91–8.  
22.  Huard B, McKee T, Bosshard C, Durual S, Matthes T, Myit S, et al. APRIL secreted by neutrophils 
binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest. 2008 
Aug;118(8):2887–95.  
23.  Miller YI, Choi S-H, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, et al. Oxidation-specific epitopes 
are danger-associated molecular patterns recognized by pattern recognition receptors of innate 
immunity. Circ Res. 2011 Jan 21;108(2):235–48.  
24.  Tarlinton D, Good-Jacobson K. Diversity among memory B cells: origin, consequences, and utility. 
Science. 2013 Sep 13;341(6151):1205–11.  
25.  Good-Jacobson KL, Shlomchik MJ. Plasticity and heterogeneity in the generation of memory B cells 
and long-lived plasma cells: the influence of germinal center interactions and dynamics. J Immunol 
Baltim Md 1950. 2010 Sep 15;185(6):3117–25.  
26.  Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006 
Jan;24(1):19–28.  
27.  Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008 
Oct;19(5):478–82.  
28.  Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity. 2012 Aug 
24;37(2):199–207.  
29.  Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy 
ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012 May 
7;209(5):1001–10.  
30.  Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, et al. Innate response 
activator B cells protect against microbial sepsis. Science. 2012 Feb 3;335(6068):597–601.  
31.  Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, et al. B lymphocytes trigger 
monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013 
Oct;19(10):1273–80.  
32.  DiLillo DJ, Horikawa M, Tedder TF. B-lymphocyte effector functions in health and disease. Immunol 
Res. 2011 Apr;49(1-3):281–92.  
33.  Bouaziz J-D, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, et al. Therapeutic B cell depletion 
impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A. 2007 Dec 
26;104(52):20878–83.  
34.  Jordö ED, Wermeling F, Chen Y, Karlsson MCI. Scavenger receptors as regulators of natural antibody 
responses and B cell activation in autoimmunity. Mol Immunol. 2011 Jun;48(11):1307–18.  
35.  Gray D, Gray M, Barr T. Innate responses of B cells. Eur J Immunol. 2007 Dec;37(12):3304–10.  
36.  Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009 Jul;9(7):491–502.  
37.  Waltner-Romen M, Falkensammer G, Rabl W, Wick G. A previously unrecognized site of local 
accumulation of mononuclear cells. The vascular-associated lymphoid tissue. J Histochem Cytochem 
Off J Histochem Soc. 1998 Dec;46(12):1347–50.  
38.  Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. Adventitial infiltrates 
associated with advanced atherosclerotic plaques: structural organization suggests generation of local 
humoral immune responses. J Pathol. 2001 Feb;193(2):263–9.  
39.  Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 
1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998 
Apr 15;101(8):1717–25.  
40.  Hamze M, Desmetz C, Berthe ML, Roger P, Boulle N, Brancherau P, et al. Characterization of resident 
B cells of vascular walls in human atherosclerotic patients. J Immunol Baltim Md 1950. 2013 Sep 
15;191(6):3006–16.  
41.  Moos MPW, John N, Gräbner R, Nossmann S, Günther B, Vollandt R, et al. The lamina adventitia is the 
major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. 
Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2386–91.  
42.  Gräbner R, Lötzer K, Döpping S, Hildner M, Radke D, Beer M, et al. Lymphotoxin beta receptor 
signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp 
Med. 2009 Jan 16;206(1):233–48.  
43.  Huan T, Zhang B, Wang Z, Joehanes R, Zhu J, Johnson AD, et al. A systems biology framework 
identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol. 2013 
Jun;33(6):1427–34.  
44.  Mantani PT, Ljungcrantz I, Andersson L, Alm R, Hedblad B, Björkbacka H, et al. Circulating CD40+ 
and CD86+ B Cell Subsets Demonstrate Opposing Associations With Risk of Stroke. Arterioscler 
Thromb Vasc Biol. 2014 Jan;34(1):211–8.  
45.  Hansson GK, Bondjers G, Bylock A, Hjalmarsson L. Ultrastructural studies on the localization of IgG in 
the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits. Exp 
Mol Pathol. 1980 Dec;33(3):302–15.  
46.  Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required 
for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 
2009 Aug 4;120(5):417–26.  
47.  Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein 
antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 
1993;23(2):95–101.  
48.  Shaw PX, Hörkkö S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, et al. Human-derived anti-
oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to 
atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol. 2001 Aug;21(8):1333–9.  
49.  Xu Q, Luef G, Weimann S, Gupta RS, Wolf H, Wick G. Staining of endothelial cells and macrophages 
in atherosclerotic lesions with human heat-shock protein-reactive antisera. Arterioscler Thromb J Vasc 
Biol Am Heart Assoc. 1993 Dec;13(12):1763–9.  
50.  Hulthe J. Antibodies to oxidized LDL in atherosclerosis development--clinical and animal studies. Clin 
Chim Acta Int J Clin Chem. 2004 Oct;348(1-2):1–8.  
51.  Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, et al. Relationship of IgG 
and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and 
cardiovascular events. J Lipid Res. 2007 Feb;48(2):425–33.  
52.  Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F. Evidence on the pathogenic role of 
auto-antibodies in acute cardiovascular diseases. Thromb Haemost. 2013 May;109(5):854–68.  
53.  Tinahones FJ, Gómez-Zumaquero JM, Garrido-Sánchez L, García-Fuentes E, Rojo-Martínez G, Esteva 
I, et al. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune 
complexes in the general population. J Lipid Res. 2005 Mar;46(3):452–7.  
54.  Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, et al. B1a B lymphocytes are 
atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in 
atherosclerotic lesions. Circ Res. 2011 Sep 30;109(8):830–40.  
55.  Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T, VADT Investigators. The levels of MDA-
LDL in circulating immune complexes predict myocardial infarction in the VADT study. 
Atherosclerosis. 2012 Oct;224(2):526–31.  
56.  Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJP, Wareham NJ, et al. Relationship of IgG 
and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and 
inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011 
Oct;52(10):1829–36.  
57.  Peters MJL, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid 
arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective 
study. Arthritis Rheum. 2009 Nov 15;61(11):1571–9.  
58.  Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE--mechanisms and 
management. Nat Rev Rheumatol. 2012 Apr;8(4):214–23.  
59.  Wada Y, Kuroda T, Murasawa A, Tanabe N, Nakano M, Gejyo F. Autoantibodies against oxidized low-
density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis. Clin Exp 
Rheumatol. 2005 Aug;23(4):482–6.  
60.  Peters MJL, van Halm VP, Nurmohamed MT, Damoiseaux J, Tervaert JWC, Twisk JWR, et al. 
Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical 
atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol. 2008 Aug;35(8):1495–
9.  
61.  Ahmed HMMS, Youssef M, Mosaad YM. Antibodies against oxidized low-density lipoprotein are 
associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Clin Rheumatol. 2010 
Nov;29(11):1237–43.  
62.  Kiani AN, Vogel-Claussen J, Arbab-Zadeh A, Magder LS, Lima J, Petri M. Semiquantified noncalcified 
coronary plaque in systemic lupus erythematosus. J Rheumatol. 2012 Dec;39(12):2286–93.  
63.  Wang J, Cheng X, Xiang M-X, Alanne-Kinnunen M, Wang J-A, Chen H, et al. IgE stimulates human 
and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/- mice. J 
Clin Invest. 2011 Sep;121(9):3564–77.  
64.  Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null 
mice. Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1892–8.  
65.  Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by 
B cells of hypercholesterolemic mice. J Clin Invest. 2002 Mar;109(6):745–53.  
66.  Ait-Oufella H, Herbin O, Bouaziz J-D, Binder CJ, Uyttenhove C, Laurans L, et al. B cell depletion 
reduces the development of atherosclerosis in mice. J Exp Med. 2010 Aug 2;207(8):1579–87.  
67.  Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, et al. Conventional B2 B cell depletion 
ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol Baltim Md 1950. 2010 
Oct 1;185(7):4410–9.  
68.  Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, Murphy D, et al. BAFF receptor deficiency 
reduces the development of atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol. 2012 
Jul;32(7):1573–6.  
69.  Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, et al. Depletion of B2 but not B1a B 
cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial 
inflammation. PloS One. 2012;7(1):e29371.  
70.  Doran AC, Lipinski MJ, Oldham SN, Garmey JC, Campbell KA, Skaflen MD, et al. B-cell aortic 
homing and atheroprotection depend on Id3. Circ Res. 2012 Jan 6;110(1):e1–12.  
71.  Wigren M, Kolbus D, Dunér P, Ljungcrantz I, Söderberg I, Björkbacka H, et al. Evidence for a role of 
regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern 
Med. 2011 May;269(5):546–56.  
72.  Schiopu A, Frendéus B, Jansson B, Söderberg I, Ljungcrantz I, Araya Z, et al. Recombinant antibodies 
to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-
)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol. 2007 Dec 11;50(24):2313–8.  
73.  Burut DFP, Karim Y, Ferns GAA. The role of immune complexes in atherogenesis. Angiology. 2010 
Oct;61(7):679–89.  
74.  Chyu K-Y, Nilsson J, Shah PK. Immune Mechanisms in Atherosclerosis and Potential for an 
Atherosclerosis Vaccine. Discov Med. 2011 May 11;11(60):403–12.  
75.  Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune 
system? Nat Rev Immunol. 2013 Mar;13(3):176–89.  
76.  Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4+CD25+ 
regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental 
autoimmune encephalomyelitis. Blood. 2008 Jan 15;111(2):715–22.  
77.  Fredrikson GN, Söderberg I, Lindholm M, Dimayuga P, Chyu K-Y, Shah PK, et al. Inhibition of 
atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler 
Thromb Vasc Biol. 2003 May 1;23(5):879–84.  
78.  Chyu K-Y, Zhao X, Reyes OS, Babbidge SM, Dimayuga PC, Yano J, et al. Immunization using an Apo 
B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-
/-) mice. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1982–9.  
79.  Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M, et al. Intranasal 
immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells 
and reduces atherosclerosis. Arterioscler Thromb Vasc Biol. 2010 May;30(5):946–52.  
80.  Herbin O, Ait-Oufella H, Yu W, Fredrikson GN, Aubier B, Perez N, et al. Regulatory T-cell response to 
apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in 
mice. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):605–12.  
81.  Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz G, et al. Induction of arteriosclerosis in 
normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb J Vasc 
Biol Am Heart Assoc. 1992 Jul;12(7):789–99.  
82.  George J, Shoenfeld Y, Afek A, Gilburd B, Keren P, Shaish A, et al. Enhanced fatty streak formation in 
C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol. 1999 
Mar;19(3):505–10.  
83.  Afek A, George J, Gilburd B, Rauova L, Goldberg I, Kopolovic J, et al. Immunization of low-density 
lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early 
atherosclerosis. J Autoimmun. 2000 Mar;14(2):115–21.  
84.  Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J. Oral tolerance with heat shock protein 65 
attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am 
Coll Cardiol. 2002 Oct 2;40(7):1333–8.  
85.  Maron R, Sukhova G, Faria A-M, Hoffmann E, Mach F, Libby P, et al. Mucosal administration of heat 
shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein 
receptor-deficient mice. Circulation. 2002 Sep 24;106(13):1708–15.  
86.  Klingenberg R, Ketelhuth DFJ, Strodthoff D, Gregori S, Hansson GK. Subcutaneous immunization with 
heat shock protein-65 reduces atherosclerosis in Apoe−/− mice. Immunobiology. 2012 May;217(5):540–
7.  
87.  George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, et al. Induction of early atherosclerosis 
in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation. 1998 Sep 
15;98(11):1108–15.  
88.  Hörkkö S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, et al. Monoclonal 
autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit 
macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999 Jan;103(1):117–28.  
89.  Binder CJ, Hartvigsen K, Chang M-K, Miller M, Broide D, Palinski W, et al. IL-5 links adaptive and 
natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest. 
2004 Aug;114(3):427–37.  
90.  Boyle JJ, Christou I, Iqbal MB, Nguyen AT, Leung VWY, Evans PC, et al. Solid-phase 
immunoglobulins IgG and IgM activate macrophages with solid-phase IgM acting via a novel scavenger 
receptor a pathway. Am J Pathol. 2012 Jul;181(1):347–61.  
91.  Smith KGC, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and 
therapeutic implications. Nat Rev Immunol. 2010 May;10(5):328–43.  
92.  Kelly JA, Griffin ME, Fava RA, Wood SG, Bessette KA, Miller ER, et al. Inhibition of arterial lesion 
progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc 
Res. 2010 Jan 1;85(1):224–31.  
93.  Ng HP, Burris RL, Nagarajan S. Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient 
hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T 
cells. J Immunol Baltim Md 1950. 2011 Dec 1;187(11):6082–93.  
94.  Mendez-Fernandez YV, Stevenson BG, Diehl CJ, Braun NA, Wade NS, Covarrubias R, et al. The 
inhibitory FcγRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-
) mice. Atherosclerosis. 2011 Jan;214(1):73–80.  
95.  Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. 
Atherosclerosis. 2008 Oct;200(2):239–46.  
96.  Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate 
dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient 
mice results in T helper cell type 1 deviation. J Exp Med. 2000 Aug 21;192(4):475–82.  
97.  Zietara N, Łyszkiewicz M, Puchałka J, Pei G, Gutierrez MG, Lienenklaus S, et al. Immunoglobulins 
drive terminal maturation of splenic dendritic cells. Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2282–
7.  
98.  Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev 
Immunol. 2010 Apr;10(4):236–47.  
99.  Karper JC, de Jager SCA, Ewing MM, de Vries MR, Bot I, van Santbrink PJ, et al. An Unexpected 
Intriguing Effect of Toll-Like Receptor Regulator RP105 (CD180) on Atherosclerosis Formation With 
Alterations on B-Cell Activation. Arterioscler Thromb Vasc Biol. 2013 Oct 10;  
100.  Opata MM, Ye Z, Hollifield M, Garvy BA. B Cell Production of Tumor Necrosis Factor in Response to 
Pneumocystis murina Infection in Mice. Infect Immun. 2013 Nov;81(11):4252–60.  
101.  Turpeinen H, Raitoharju E, Oksanen A, Oksala N, Levula M, Lyytikäinen L-P, et al. Proprotein 
convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines 
BAFF and APRIL. Atherosclerosis. 2011 Dec;219(2):799–806.  
 
 
 
 
 
 
 
 
 
Figure Legend 
A. B cell development and subsets. B1 cells develop primarily from fetal liver and self-maintain 
in the adult. B1 cells are the source of natural IgM antibodies that target antigens such as oxidized 
phospholipids. B2 cells develop from adult bone marrow stem cells and undergo a series of 
differentiation steps in the bone marrow, then leave as immature/transitional B cells and further 
differentiate into either marginal zone or follicular B cells in the spleen. B2 cell activation leads to 
short-lived plasma cell differentiation or, in the case of T cell dependent responses, germinal centre 
formation, which results in affinity maturation of the B cell clone and formation of memory B cells 
and long-lived plasma cells, which can persist in specific bone marrow niches until ntigen 
reencounter. B. B cell regulation of atherosclerosis. Natural antibodies and other IgM targeting 
oxLDL, primarily but not exclusively from B1 cells, is thought to be atheroprotective. The potential 
pro-atherogenic functions of B2 cells include production of IgG2 antibodies that activate 
macrophages via Fc receptors, activation of pro-atherogenic Th1 CD4 T cells, or production of pro-
inflammatory T cells. B cells may act remotely from peripheral lymphoid organs or locally from the 
adventitia and atherosclerotic plaque.  
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